Abstract:Background Hepatocyte growth factor(HGF) can induce non-small cell lung cancer(NSCLC) cells exerting resistance to epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in vitro,suggesting that HGF induced c-Met phosphorylation may be associated with the mechanism of erlotinib resistance in sensitive NSCLC.Objective The study aimed to demonstrate that c-Met inhibitor SU11274 can reverse the erlotinib resistance induced by HGF in sensitive NSCLC cells in nude mice.Methods This study was conducted from March 2014 to January 2015.Two cell lines including H292 and human embryonic fibroblast MRC-5 were chosen.The HGF produced by MRC-5 cells in cell culture supernatants was quantitated by enzyme-linked immunosorbent assay(ELISA).The proliferation of H292 cells was measured by using MTT assay and the expressions of c-Met and its downstream signaling proteins were examined by Western blotting.We selected forty-nine 6-week old nude mice and equally divided them into 7 groups,group C (control group),group H,group HS,group HD,group E,group HE,group HES,treated with H292 cell suspension,HGF,HGF+SU11274,HGF+1% DMSO,erlotinib,HGF+erlotinib,HGF+erlotinib+SU11274,respectively.The tumor growth was observed and the growth curve was drawn.The tumor weight was recorded.The expressions of c-Met and downstream signaling proteins in tumor tissues were determined via immunohistochemistry.Results ELISA assay found that the HGF level in the culture supernatant of MRC-5 cells was (1 262±90) pg/ml.MTT assay showed that in the mixture of H292 and MRC-5 cells culture supernatant with erlotinib concentration of IC50,the proliferation of H292 cells was 97.07%.The expressions of p-Met,p-STAT3,p-AKT and p-ERK1/2 in the culture supernatant of H292 with MRC-5 cells were higher than those in the H292 cell culture supernatant(P<0.05).Intervention method and duration exerted significant interaction effects on the tumor volume(P<0.001).Intervention method produced main effect on the tumor volume(P<0.001).Intervention duration had main effect on the tumor volume(P<0.001).The tumor volume was smaller in HES group than in HE group measured on the 7th,11th,14th,18th,21st and 25th days of intervention (P<0.05).The tumor mass differed significantly between the groups(F=39.120,P<0.001).HES group had less tumor mass than HE group did(P<0.05).Significant differences in the expressions of c-Met,p-Met,p-STAT3,p-AKT and p-ERK1/2 were found between the groups(P<0.05).The expressions of c-Met,p-Met,and p-STAT3 proteins were lower in HES group than those in HE group(P<0.05).Conclusion HGF secreted by MRC-5 induces erlotinib resistance in H292 cells in nude mice.c-Met inhibitor SU11274 reverses the resistance of HGF-induced sensitive NSCLC cells to erlotinib in vivo.The mechanism may be related to the inhibition of HGF-induced activation of c-Met and its signaling pathway proteins.

Ehf Enhances Malignancy By Modulating Akt And Mapk/Erk Signaling In Non-Small Cell Lung Cancer Cells

Blockage of ETS Homologous Factor Inhibits the Proliferation and Invasion of Gastric Cancer Cells Through the C-Met Pathway

Increased Expression of EHF Via Gene Amplification Contributes to the Activation of HER Family Signaling and Associates with Poor Survival in Gastric Cancer

Overexpression of ELF3 Facilitates Cell Growth and Metastasis Through PI3K/Akt and ERK Signaling Pathways in Non-Small Cell Lung Cancer

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

EGF Upregulates RFPL3 and Htert Via the MEK Signaling Pathway in Non‑small Cell Lung Cancer Cells.

Homoharringtonine promotes non-small-cell lung cancer cell death via modulating HIF-1α/ERβ/E2F1 feedforward loop

Transcription factor EHF drives cholangiocarcinoma development through transcriptional activation of glioma-associated oncogene homolog 1 and chemokine CCL2

Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells

EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines

Mechanism of SU11274 Reversing the Resistance to Erlotinib Induced by Hepatocyte Growth Factor in Non-small Cell Lung Cancer Cells

Overexpression of P-Akt, P-Mtor and P-Eif4e Proteins Associates with Metastasis and Unfavorable Prognosis in Non-Small Cell Lung Cancer.

Elevated HNF1A expression promotes radiation-resistance via driving PI3K/AKT signaling pathway in esophageal squamous cell carcinoma cells

Hypoxia drives estrogen receptor β-mediated cell growth via transcription activation in non-small cell lung cancer

Increased Expression of Ehf Contributes to Thyroid Tumorigenesis Through Transcriptionally Regulating Her2 and Her3

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

Enoyl-coenzyme A hydratase short chain 1 silencing attenuates the proliferation of hepatocellular carcinoma by inhibiting epidermal growth factor signaling in vitro and in vivo.

Hgfk1 is Associated with A Better Prognostis and Reverses Inhibition by Gefitinib in Nsclc Cases